NCT04917861View on ClinicalTrials.gov

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

PHASE2CompletedINTERVENTIONAL
Enrollment

808

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

July 26, 2024

Study Completion Date

July 26, 2024

Conditions
Zika Virus
Interventions
BIOLOGICAL

mRNA-1893

Solution for injection

BIOLOGICAL

Placebo

0.9% sodium chloride solution for injection

Trial Locations (11)

51106

Meridian Clinical Research (Sioux City, IA), Sioux City

66219

Johnson County Clin-Trials, Lenexa

76135

Benchmark Research - Fort Worth, Fort Worth

00784

Clinical Research Puerto Rico, Inc., Guayama

00713

Ponce Medical School Foundation, Inc., Ponce

00716

Ponce Medical School Foundation, Inc., Ponce

00909

Clinical Research Puerto Rico, Inc., San Juan

Latin Clinical Trial Center, Inc., San Juan

00917

GCM Medical Group, PSC, San Juan

00918

Carribean Medical Research, San Juan

00935

University of Puerto Rico, San Juan

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY